Co-Authors
This is a "connection" page, showing publications co-authored by KEITH FRANCIS FOURNIER and KANWAL PRATAP SINGH RAGHAV.
Connection Strength
2.158
-
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol. 2024 Jan; 31(1):614-621.
Score: 0.242
-
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
Score: 0.235
-
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open. 2021 08 02; 4(8):e2119934.
Score: 0.207
-
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
Score: 0.206
-
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.
Score: 0.193
-
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654.
Score: 0.156
-
Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193.
Score: 0.148
-
Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4.
Score: 0.133
-
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7.
Score: 0.121
-
Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity? J Am Coll Surg. 2011 May; 212(5):906; author reply 907.
Score: 0.102
-
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 Feb 05; 7(2):e240260.
Score: 0.062
-
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv. 2023 Sep 11.
Score: 0.060
-
Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg. 2023 Feb 28; 408(1):110.
Score: 0.058
-
Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases. Am J Surg Pathol. 2022 10 01; 46(10):1352-1363.
Score: 0.055
-
Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases. Int J Gynecol Pathol. 2022 Jan 01; 41(1):59-67.
Score: 0.053
-
Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol. 2021 01; 45(1):45-58.
Score: 0.050
-
Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672.
Score: 0.039
-
Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331.
Score: 0.039